Harbour Investments’s Axsome Therapeutics AXSM Stock Holding History

Harbour Investments’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1K	Hold	60	–	–	﹤0.01%	3256
2025 Q4	$11K	Hold	60	–	–	﹤0.01%	2697
2025 Q3	$7.29K	Hold	60	–	–	﹤0.01%	2823
2025 Q2	$6.26K	Hold	60	–	–	﹤0.01%	2785
2025 Q1	$7K	Buy	60 +36	+150%	+$4.1K	﹤0.01%	2685
2024 Q4	$2.03K	Buy	+24	New	+$2.21K	﹤0.01%	3017
2023 Q4	–	Sell	-65	Closed	-$4.54K	–	3131
2023 Q3	$4.54K	Sell	65 -300	-82%	-$22.4K	﹤0.01%	2304
2023 Q2	$26.2K	Buy	365 +300	+462%	+$22.1K	﹤0.01%	1649
2023 Q1	$4.01K	Hold	65	–	–	﹤0.01%	2354
2022 Q4	$5.01K	Buy	+65	New	+$3.88K	﹤0.01%	2216
2021 Q4	–	Sell	-2	Closed	–	–	2694
2021 Q3	$0	Hold	2	–	–	﹤0.01%	3723
2021 Q2	$0	Hold	2	–	–	﹤0.01%	3758
2021 Q1	$0	Buy	+2	New	+$141	﹤0.01%	3591

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbour Investments's AXSM Position: Q1 2026 in Review

Harbour Investments held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 60 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3256.

Harbour Investments first reported a position in AXSM in Q1 2021 and has held it in 13 quarters since. The position peaked at $26.2K in Q2 2023. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Harbour Investments held 60 shares of Axsome Therapeutics worth $10.1K as of Q1 2026.
Harbour Investments left its Axsome Therapeutics share count unchanged in Q1 2026.
Axsome Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #3256 holding.
Harbour Investments first reported a position in Axsome Therapeutics in Q1 2021 and has held it in 13 quarters since.
Harbour Investments's Axsome Therapeutics position peaked at $26.2K in Q2 2023.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.